Fig. 4From: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case seriesChange of tumor burden in off-target lesions. Changes of tumor burden for two patients who had measurable uninjected lesions are shown as a function of time measured in weeks. The time of T-VEC treatment is set at 0. End of line indicates time of observationBack to article page